News

Canada-based Portage Biotech holds 54% equity interest in Biohaven Pharmaceutical Holding Company. With the completion of FDA review, Biohaven now plans to immediately proceed with a Phase I

HLD-200 uses Ironshore’s drug delivery platform, DELEXIS, to enable nighttime dosing of these patients. The multicenter, double-blind, randomized, placebo-controlled, parallel group Phase III trial (AHEAD) is designed to

Promacta is a once-daily oral thrombopoietin (TPO) receptor agonist that works by inducing stimulation and differentiation of megakaryocytes from bone marrow stem cells to increase platelet production. The

The fully randomized placebo-controlled trial, conducted by Moore Clinical Research, an independent FDA-compliant contract research organization (CRO), compares the performance of HSRx’s acne treatment product with that of

Retinitis pigmentosa leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina that sense light), resulting in severe vision loss and blindness. With

Talazoparib is currently in a Phase III trial designed to treat patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.

Bavituximab is Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor and durvalumab is AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, while both are investigational immunotherapies with different mechanisms that assist the

The global clinical trial technology company has centralized development of its SaaS solutions in its Boston office due to the area’s unique combination of expert development talent, biopharmaceutical

Her addition to the senior leadership team further solidifies EAS as the leading consulting company in regulatory matters pertaining to all FDA regulated areas including OTCs, pharmaceuticals, cosmetics,